Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Novel Protease-Mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances Directionality of CAR-T Cell Activity and Improves Target Cell Specificity

Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori

Blood (2022) 140 (Supplement 1): 4533–4534.

https://doi.org/10.1182/blood-2022-165658

Published: 2022

Journal Articles

MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Daisuke Watanabe, MD, PhD, Hiroki Akiyama, MD, PhD, Kouhei Yamamoto, Takeo Fujiwara, MD, Emiko Sakaida, MDPhD, Yoko Edahiro, MD PhD, Misa Imai, PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Norihiko Kawamata, MD, PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139162

Published: 2020

Journal Articles

A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): "Double Arm" CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD, PhD, BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-140642

Published: 2020

Journal Articles

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Watanabe Daisuke, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Kouhei Yamamoto, Takeo Fujiwara, MD, Yoko Edahiro, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Tetsuya Fukuda, MD PhD, Ayako Arai, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata

Blood (2019) 134 (Supplement_1): 1690.

https://doi.org/10.1182/blood-2019-122652

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

A Novel Cell Line, Tnet-2, Derived from "Triple-Negative" Essential Thrombocythemia

Satoru Aoyama, MD MMSc, Toshikage Nagao, MD PhD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, Shinya Ishida, MD, Ayako Nogami, MD, PhD, Yoshihiro Umezawa, MD, Ken Watanabe, MD PhD, Masahide Yamamoto, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata, MD

Blood (2018) 132 (Supplement 1): 5493.

https://doi.org/10.1182/blood-2018-99-114457

Published: 2018

NARROW

Novel Protease-Mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances Directionality of CAR-T Cell Activity and Improves Target Cell Specificity

MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations

A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): "Double Arm" CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

A Novel Cell Line, Tnet-2, Derived from "Triple-Negative" Essential Thrombocythemia

Email alerts

ASH Publications

American Society of Hematology

Novel Protease-Mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances Directionality of CAR-T Cell Activity and Improves Target Cell Specificity

MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations

A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): "Double Arm" CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

A Novel Cell Line, Tnet-2, Derived from "Triple-Negative" Essential Thrombocythemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only